AbbVie Signs an Exclusive Agreement with Scripps Research to Develop New Therapies Targeting Multiple Therapeutic Areas
Shots:
- Scripps Research to receive up front- development & commercialization milestones- option exercise fee and royalties on sales of new therapies and will conduct pre-clinical R&D activities and P-I studies (in some cases) while AbbVie get an exclusive option to further develop and commercialize therapies for cancer- immunology- neurology and fibrosis
- The collaboration marks the expansion of companies’ partnership signed in 2018- to develop T-cell therapies targeting solid tumors
- Additionally- Scripps Research will offer preclinical programs to AbbVie of mutual interest/yr. for consideration to be included in the collaboration. The companies will also work to advance CD3 bispecific against oncology targets selected by AbbVie
Click here to read full press release/ article | Ref: AbbVie | Image: AbbVie
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com